Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Just Group Jumps 23% On Regulatory Decision

Mon, 10th Dec 2018 10:59

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC Health, up 1.3%. The UAE-based private healthcare operator reiterated its previous annual earnings guidance, citing supportive industry dynamics and continued positive operational developments. For 2018, NMC Health said it expects to record 24% year-on-year growth in total revenue, with organic revenue growth of 15%. Total revenue in 2017 stood at USD1.60 billion, with organic growth have contributed roughly 16% that year. A 24% increase suggests 2018 revenue will be just short of USD2 billion. Earnings before interest, tax, depreciation and amortisation for 2018 is predicted to total USD480 million, up 36% from USD353.4 million a year ago. NMC also said it has secured a contract to manage a hospital in Seychelles.----------Informa, up 1.1%. JPMorgan upgraded the exhibitions and business information group to Overweight from Neutral.----------FTSE 100 - LOSERS----------SSE, down 3.0%. Deutsche Bank downgraded the energy supplier to Hold from Buy.----------Barratt Developments, down 1.9%, Taylor Wimpey, down 1.2%, Berkeley Group, down 0.7%. Peel Hunt downgraded Barratt and Berkeley to Add from Buy and cut Taylor Wimpey to Hold from Add. ----------FTSE 250 - WINNERS----------Just Group, up 23%. The life insurer said the UK Prudential Regulation Authority's policy statement on equity release mortgages being held to back annuity liabilities will not affect its business pricing. Just Group said it has already aligned its new business pricing with the expected capital requirements from the PRA's consultation paper. Monday's policy statement follows a three-month consultation following the release of the regulator's consultation paper on equity release mortgages. Just Group, in particular, said it "welcomes" the confirmation that transitional relief will remain available for pre-2016 business. Just Group said that, following the release of the policy statement, the minimum deferment rate for allowing no negative equity risks will be 1% with a 13% property volatility rate - which is towards the lower end of the range considered in the consultation paper. The financial services regulator confirmed it has no plans to apply effective value tests to other assets.----------Spire Healthcare, up 9.5%. Morgan Stanley raised the private healthcare company to Overweight from Equal Weight. ----------FTSE 250 - LOSERS----------Thomas Cook, down 8.7% at 28.20p. UBS cut its price target on the travel agent to 34p from 60p and reiterated its Neutral rating on the stock. Thomas Cook will be demoted from the FTSE 250 as part of the FTSE Russell quarterly review changes that come into effect later this month. ----------Crest Nicholson, down 6.0%. Peel Hunt downgraded the housebuilder to Reduce from Hold. ----------OTHER MAIN MARKET AND AIM - WINNERS----------ValiRX, up 27%. The biotechnology firm said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer. The study was undertaken using a non-parametric approach - both the well-established Friedman test and the most up-to-date statistical method, repeated measures multiple correlation analysis. This analysis revealed that volunteers treated with VAL201 displayed a "statistically significant" correlation for reductions over time in the amount of testosterone and prostate specific antigen, which stimulate the progression of prostate cancer.----------Hollywood Bowl, up 7.5%. The ten-pin bowling operator announced a special dividend for the second straight year as it reported a double-digit rise in annual profit. In the financial year ended September 30, the ten-pin bowling centre operator increased its pretax profit 13% to GBP23.9 million from GBP21.1 million last year. Revenue increased 5.7% to GBP120.5 million from GB114.0 million the year before. Hollywood Bowl reported a like-for-like revenue increase of 1.8% in the period. The company hiked its total dividend by 17% to 10.59 pence from 9.08p paid out last year. Hollywood Bowl's higher total dividend included a 30% increase in special dividend to 4.33p from 3.33p. The company opened two new centres during the period, in Dagenham and Yeovil, while closing one in Gravesend, taking its total to 58.----------OTHER MAIN MARKET AND AIM - LOSERS----------Interserve, down 51%. The outsourcer said it secured GBP25 million contract from Cwm Taf University Health Board with works commencing in December, providing some positive news a day after it admitted shareholders face "material dilution" from refinancing plan being discussed with creditors. On Saturday, The Financial Times said Interserve's shareholders could lose everything under the terms of a rescue finance plan being discussed between Interserve and creditors. Under the terms of the proposed plan, banks and other debt holders would take a significant loss as part of a debt-for-equity swap, while public shareholders would be virtually wiped out, the newspaper said. On Sunday, Interserve confirmed its lenders are engaged in constructive discussions regarding the agreement and implementation of a deleveraging plan, which it said would deliver a strong balance sheet.----------Photo-Me International, down 10%. The photo booth operator said its profit dropped in the first half of its current financial year due to the lower machine sales in the UK. Photo-Me said pretax profit declined 13% to GBP26.0 million in the six months to the end of October from GBP32.9 million reported for the same period a year earlier, as revenue slipped to GBP119.8 million from GBP122.2 million. The company said revenue was hurt by restructuring in Photo-Me Retail, which resulted in GBP5.3 million reduction in revenue. Excluding that, underlying revenue was up 2.5%. The company said pretax profit took a hit from lower B2B revenue and machine sales activity, especially in the UK, Photo-Me noted. Photo-Me declared an interim dividend of 3.71 pence a share, unchanged year-on-year. ----------

More News
9 Jan 2019 14:57

ValiRx gives NHS Long Term Plan its seal of approval

(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.

Read more
9 Jan 2019 11:25

ValiRx Backs New Long-Term UK Government Plan For NHS

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan."The government's recently announced ten-year a

Read more
18 Dec 2018 15:53

VAL401 results accepted for journal publication, says ValiRx

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.

Read more
10 Dec 2018 11:07

ValiRx releases positive data from recent VAL201 testing

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

Read more
10 Dec 2018 09:06

ValiRx Reports Positive VAL201 Effect On Patients With Prostate Cancer

LONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.The up

Read more
17 Oct 2018 08:36

ValiRx enters finals stages of clinical trials on VAL201

(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.

Read more
25 Sep 2018 13:23

ValiRx Half Year Loss Widens On Expenses And Share Option Charge

LONDON (Alliance News) - Life science company ValiRx PLC on Tuesday reported a widened loss in the first half of 2018 due to expenses and a sizeable share option charge.The company's to

Read more
6 Sep 2018 11:38

ValiRx Says Clinical Study For Lung Cancer Drug VAL401 Is Approved

LONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal in ValiRx were

Read more
6 Sep 2018 09:05

ValiRx enters 'very exciting' phase for cancer therapies

(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
11 May 2018 16:43

Nicholas Slater Increases ValiRx Stake To 4.5% From 2.7% (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his

Read more
4 May 2018 17:08

ValiRx Raises GBP950,000 Through Placing To Progress Pipeline (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down

Read more
25 Apr 2018 13:41

"Major" Milestone As ValiRx's VAL201 Is Granted Patent In EU

LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a

Read more
19 Apr 2018 12:41

ValiRx Posts Positive Results From VAL101 Compound Pre-Clinical Trials

LONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.